Novo Nordisk Launches Esperoct [antihemophilic factor (recombinant), glycopegylated-exei] to Treat Hemophilia A in the US

 Novo Nordisk Launches Esperoct [antihemophilic factor (recombinant), glycopegylated-exei] to Treat Hemophilia A in the US

Novo Nordisk Launches Esperoct [antihemophilic factor (recombinant), glycopegylated-exei] to Treat Hemophilia A in the US

Shots:

  • Novo Nordisk reports the availability of Esperoct in the US to treat adults and children with hemophilia A as it replaces the clotting Factor VIII that people with hemophilia A are missing and maintains Factor VIII levels longer which help in reducing the frequency of bleeding with less frequent dosing
  • In 2019, Esperoct has received the US FDA’s approval based on 5 studies assessing Esperoct (q2w) in 270 patients with hemophilia A and was safe & well tolerated
  • Esperoct is an injectable therapy to reduce the number of bleeding episodes in people with hemophilia A. Additionally, Novo Nordisk offers patient assistance program (NovoSecure), allowing patients administering the therapy to apply for product assistance

Click here to­ read full press release/ article | Ref: Novo Nordisk | Image: The Business Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post